Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating income | -$9.30M | -$26.3M | -$58.9M | -$79.9M | -$104M | -$133M |
| Net income | -$9.34M | -$26.3M | -$55.3M | -$69.1M | -$86.5M | -$120M |
| EPS (diluted) | -$6.05 | -$1.91 | -$1.32 | -$1.62 | -$1.51 | -$2.01 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$7.76M | -$23.7M | -$50.3M | -$50.1M | -$69.8M | -$95.1M |
| Capital expenditures | $312K | $661K | $559K | $770K | $664K | $141K |
| Free cash flow | -$8.07M | -$24.4M | -$50.8M | -$50.9M | -$70.4M | -$95.3M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $15.2M | $302M | $251M | $58.0M | $92.0M | $77.4M |
| Total assets | $16.0M | $307M | $266M | $226M | $364M | $283M |
| Total liabilities | $2.00M | $4.96M | $8.35M | $21.6M | $20.4M | $23.4M |
| Shareholders' equity | -$13.6M | $302M | $258M | $204M | $343M | $259M |
| Retained earnings | -$14.1M | -$40.4M | -$95.7M | -$165M | -$251M | -$371M |
| Shares (wtd avg diluted) | 1.83M | 13.8M | 41.9M | 42.7M | 57.2M | 59.6M |
Every figure is extracted from Tyra Biosciences, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.